Higher dose furmonertinib versus osimertinib for lung cancer with brain metastases
Treatments studied
Part of Brain & nervous system, Cancer, Lungs & breathing clinical trials.
This trial compares a higher dose of a newer targeted pill (furmonertinib) to a standard targeted pill (osimertinib) for advanced lung cancer with an EGFR mutation that has spread to the brain. The goal is to see if the higher dose works better at controlling the cancer in the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Adults aged 18 to 80 years old
- Diagnosed with non-small cell lung cancer (NSCLC) that has a component of adenocarcinoma
- Has a specific EGFR gene mutation (including uncommon ones) found in tissue or blood
- Has brain metastases that are stable and do not need immediate treatment
- Has not received prior treatment with EGFR TKI drugs (like osimertinib or erlotinib)
- Is generally in good health with normal organ function (blood counts, liver, kidney)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted therapy called furmonertinib combined with chemotherapy against the current standard osimertinib for people with a specific type of non-small cell lung cancer (NSCLC) that has spread to the brain. It aims to find a better treatment option for patients whose cancer cells have a common EGFR mutation.
This study tests two doses of furmonertinib (a targeted pill) combined with chemotherapy for people with a specific EGFR gene change in lung cancer that has spread to the brain. It aims to see if the higher dose works better while keeping side effects manageable.
This trial tests a double dose (160 mg) of a newer targeted pill called furmonertinib for people whose lung cancer has slowly gotten worse while taking osimertinib. It might help control the cancer when the first targeted therapy is starting to lose its effect.
This trial tests a new way to give a targeted therapy (furmonertinib) to people with a specific type of lung cancer that has spread to the lining of the brain. It uses a higher, pulsing dose to try to get more medicine into the brain fluid and stop the cancer there.
This trial tests a higher dose of the targeted therapy Furmonertinib, either alone or with chemotherapy, for people with advanced non-small cell lung cancer that has progressed after initial treatment with a third-generation EGFR inhibitor like Osimertinib or Almonertinib.
This trial tests a combination of two targeted pills (furmonertinib and anlotinib) as a first treatment for people with advanced EGFR-mutant non-small cell lung cancer that has spread to the brain. It aims to see if this combination works better than the standard approach for controlling the cancer.
Hear when a new Lung Cancer, Nonsmall Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.